Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA)

The Biomedical Advanced Research and Development Authority (BARDA) is issuing BAA‑23‑100‑SOL‑00004 for the development of SARS‑CoV‑2 medical countermeasures and, optionally, additional therapeutics on the same platform targeting respiratory viruses or hemorrhagic‑fever agents. Offerors must first submit a Market Research Abstract and are strongly encouraged to coordinate with the Technical POC (FASTxBAA @hhs.gov) to obtain feedback. Proposals must include all available efficacy data against the latest viral variants, a detailed, non‑severable Statement of Work (SOW) organized into discrete work segments with go/no‑go milestones, and a comprehensive development approach covering experimental design, acceptance criteria, alternative strategies, risk mitigation, regulatory pathway, cost‑of‑goods reduction, and manufacturing plans. The technical proposal must follow BARDA’s cover‑page requirements, embed the Government Notice for Handling and Submitting Proposals behind the title page, and explicitly avoid any gain‑of‑function research. Evaluation will be based on technical merit, program importance, and cost realism, with option periods available for advancing candidates against secondary targets that have defined animal models and regulatory pathways.

Notice ID

8170c4735df64714adb2d1f8ce8671b1

Solicitation Number

BAA-23-100-SOL-00004

NAICS Code

541714

Classification Code

AN13